trending Market Intelligence /marketintelligence/en/news-insights/trending/cdPjRHDtLqWKvQggQ2_L-A2 content esgSubNav
In This List

Mesoblast raises US$40M in placement

Case Study

Identifying PPE Suppliers During the Pandemic


Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage


COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Mesoblast raises US$40M in placement

Mesoblast Ltd. completed a fully underwritten institutional placement of 26.25 million new shares, priced at A$2 per share, to global institutional investors.

The company plans to use the proceeds of about US$40 million for its ongoing phase 3 clinical programs including chronic heart failure, and for manufacturing requirements related to product commercialization.

Bell Potter Securities Ltd. acted as lead manager and underwriter to the placement.

As of March 24, US$1 was equivalent to A$1.31.